The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Seacations are on the cards.
Our breathalyser would be handy:
https://www.chroniclelive.co.uk/whats-on/travel-tourism/fancy-seacation-hays-travel-pitches-20218619
Actually I enjoyed the chat about PMO and SNG - not into those stocks at all.
As for why this is not flying - your guess is as good as mine.
None of the big majors are making a move to buy it out. Once someone does FOMO will kick in.
In the meantime, expect a trickle up and then a sudden BOOM once it gets noticed like COVID shares have recently.
Agree
I am invested in all three in varying quantities.
CWR - Their licensing model is better (ARM esque). It allows them to spend on R&D too.
ITM - ready for roll out. Lots of potential. But - looks like a monoproduct that produces H2 only.
AFC - after reading their annual report and with most recent developments - looks more like a winner in the coming year.
If you are still looking for some unloved stock with potential - look at EQT. Slow, steady and gradual rise expected, particularly after their Aries case in the US has been withdrawn with prejudice. So, investors are expecting a rise on Monday.
Thanks all.
Much appreciated.
I didn't realise you could offset losses against other investments too.
I was simply trying to crystallise some gains and move from my trading to my ISA account.
BTW, I have used my ISA allowance this year, so was hoping to sell on 5.4.21 and buy on 6.4.21. If the price doesn't rise, that should be fine, shouldn't it?
Slightly off topic so apols for that.
I have bought AFC many many years ago and now need to Bed and ISA them.
Since they have grown in price, I am unable to decide on how many should I sell to be below the CGT cap (£12,300). I am aware that you need to deduct expenses etc when calculating CGT.
My Q is - can anyone please point me to a simple calculator spreadsheet for UK shares that'll allow me to input figures and voila! the answer will be there. I tried the HMRC tool, but probably didn't understand it well and so calcs got wrong. (I am poor in maths!!)
Thanks
That's exactly my point at 11.15 post.
In the lab, it works well. In clinical deployment, wait with bated breath!!
GLA.
Chesh
If that paragraph would have followed the 16/40 one, I would have thought it to be accurate. The DVRG scientists worked in the lab. The trials were in Ireland.
If it was 16/16 for DVRG, that would be 100% concordance. It would be huge and potentially applicable for emergency use approval for deployment. My guess is, it was not, hence the delay in deployment.
T.Rat
If all of those 16 ALSO tested positive by our method, then that's brilliant. My guess is they didn't. Hence the RNS doesn't go into that.
(My response may overlap with others - all of us typing at the same time :-) )
16 out of 40 tested positive for covid. What is not clear from the RNS is how many of those 16 also tested positive by our method.
Thanks
I hope I have. Lots of ££ invested here.
What did I misunderstand in terms of:
1. The actual numbers (16/40)
2. MHRA TTP - which of the Desirable and Acceptable are achieved? https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/966283/Breath_TPP_Final_version_v1.0.pdf
I am NOT impatient, just being constructively critical in understanding what the company is attempting to convey.
Thanks
I am not too impressed with today's RNS. The last para starts out with giving numbers (16 out of 40) that's less than 50%.
'In addition, under the clinical trial supervision of the Royal College of Surgeons, Ireland, 40 subjects, 16 of which were independently confirmed as COVID19 positive with PCR[iii] tests, provided breath samples that were tested on the Microtox® BT nano-optofluidic chip surface with Affimer® reagents ("Avacta Group")[iv] and Optimers ("Aptamer Group")[v] together the ("Binding Agents").
The breath samples detected binding on the nano-optofluidic chip with a secondary antibody to the Spike Protein which was initially selected for the isolated spike protein work. Detection of the live virus was confirmed indicating 9 times increase in the digital spectrum signal on the Microtox® BT when compared to controls of nano-optofluidic chips with binding agent; and 19 times increase in signal with nano-optofluidic chips without binding agents. Additional digital background noise was indicated due to the non-specific binding of the antibody. Further data is required to confirm the same high sensitivity and specificity is achieved on breath test clinical trials which are underway.'
These sentences don't tell us how many of the 19 who tested positive by other methods ALSO tested +ve by DVRG method!
Am I missing something?
Bought on 19.04.2017 at 19.15 p
Helpful, informative conversation on this thread.
Has anyone considered the challenge to building so many batteries, in particular the Rare Earths/ Metals required for building them and the challenges around supply? When you consider that a majority of supply is from China and major democracies are trying to wean away from Chinese hostage taking, are the car companies missing something?
https://www.ft.com/content/d3ed83f4-19bc-4d16-b510-415749c032c1
https://investingnews.com/daily/resource-investing/critical-metals-investing/rare-earth-investing/rare-earth-producing-countries/
From a supply chair security point of view - is there an alternative to H2?
One always considers the competition from batteries and EVs. However, the challenge is having enough of the Rare Earths / Rare metals that go in the batteries to supply the battery makers.
I do think that's where H2 scores higher than others. The versatility of the gas and its ability to be produced at scale is more longer lasting than betting on EV alone.
https://asia.nikkei.com/Politics/International-relations/Indo-Pacific/Quad-tightens-rare-earth-cooperation-to-counter-China
@TradingDutchman - you need to let CPX know about your discovery. They may not know about it?
@showmedamane - nothing in the article to suggest use of DMTR processes.
Is there a link to a scientific paper in a journal?
Do their collaborators in the US use our tech?
One can never expect logic from the stock market.
I have owned LSE stock for more than a decade. I don't pay much attention to the daily change in its share price since it is a safe stock.
Yesterday (5.3.21) it tanked. By a full 14.38% (1364p). I thought something terrible had happened due to Brexit.
Discovered it had made some of the highest profit and was giving out a larger dividend.
What does the market know, eh?!
Do we know anything about their potential to take over the market vis a vis CPX? After all, they have Kyocera behind them.
TiqTiq - I had the same thought (why not Sheffield buses on ITM produced H2) when I received their email. I do agree with Toneman and Lfclfc5 though.
Just because the bus that transports school children is hydrogen powered, it wouldn't make folks go out and buy a hydrogen car, would it?
On the other hand if National Express, First, Aviva and the like start to run their national vehicle strategy on Hydrogen (particularly National Express and the other £1 one) - now we are talking!!